Flu season is approaching, YSB (09885) "ensuring supply" drives sales growth.

Recently, many regions across the country have experienced a strong cold wave weather, and respiratory infectious diseases such as influenza have entered a peak period. Grassroots medical institutions are facing a dual test of drug supply and diagnostic services. The latest monitoring data from the National Influenza Center shows that influenza activity in southern provinces of China is on the rise, with an increase in the positivity rate of the H3N2 influenza virus in some areas. The digital pharmacy platform YSB (09885) has actively responded to the medication needs at the grassroots level, providing effective support to strengthen the "supply defense line" at the grassroots level. To ensure the stable supply of essential drugs, YSB has established deep strategic cooperation with multiple domestic pharmaceutical companies to achieve full coverage of all types of influenza treatment drugs such as Oseltamivir. At the same time, the platform tracks the changes in drug demand at grassroots terminals in real time through its intelligent supply chain system, achieving precise inventory management and further ensuring the stable supply and distribution efficiency of drugs. The peak season of influenza has also led to a significant increase in the sales of related drugs on the platform. According to sales data disclosed by YSB, since October 2025, the overall sales of influenza drugs on the YSB platform have increased by 36% year-on-year, with a particularly strong demand for clinically commonly used Oseltamivir phosphate granules and capsules, with a sales volume increasing by 120% year-on-year. The platform's own brand "Joy Pharmacist" cold medicine also achieved a sales volume growth of over 135% year-on-year due to its high cost-performance advantage. In addition, YSB empowers the diagnosis and treatment end of grassroots healthcare institutions through the "Spectrum Hut" grassroots intelligent medical solution, further alleviating the pressure of grassroots prevention and control. According to YSB, its core product, the Immune Mini Box, supports "minute-level" rapid detection of influenza A and B after throat swab sampling, forming a good synergy with the drug supply chain business, with a month-on-month increase of over 60% in related tests in October. Some analysts believe that timely replenishment and precise allocation of grassroots medical resources are key to prevention and control, especially in the background of high influenza prevalence and cold wave weather. By integrating upstream pharmaceutical resources, mid-stage intelligent scheduling, and downstream intelligent testing services, YSB will further enhance its integrated service capabilities in covering drug supply and diagnostic support, helping grassroots response in this round of influenza season.